GlobeImmune to Present at 12th Annual Needham Healthcare Conference

LOUISVILLE, Colo., April 18, 2013 - GlobeImmune, Inc., today announced that Timothy C. Rodell, M.D., president and chief executive officer of GlobeImmune, will present at the 12th Annual Needham Healthcare Conference at 2:20 p.m. EDT on Tuesday, April 30, at The Westin New York Grand Central Hotel in New York.  Dr...

LOUISVILLE, Colo., April 18, 2013 - GlobeImmune, Inc., today announced that Timothy C. Rodell, M.D., president and chief executive officer of GlobeImmune, will present at the 12th Annual Needham Healthcare Conference at 2:20 p.m. EDT on Tuesday, April 30, at The Westin New York Grand Central Hotel in New York.  Dr. Rodell will provide an update on the company's Tarmogen^® platform and product candidates, including GI-4000 for the treatment of Ras-mutated cancers, GI-6207 for cancers expressing carcinoembryonic antigen (CEA), GI-6301 for cancers expressing the brachyury protein and GI-13020 for the treatment of chronic hepatitis B infection.

About GlobeImmune

GlobeImmune is a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. Tarmogens activate the immune system by stimulating cellular immunity, known as T cell immunity, in contrast to traditional vaccines that predominately stimulate antibody production.  To date, Tarmogen product candidates have been generally well tolerated in clinical trials for multiple disease indications and are efficient to manufacture.  In May 2009, the company entered into a collaboration agreement with Celgene Corporation focused on the discovery, development and commercialization of product candidates for the treatment of cancer.  In October 2011, the company entered into a worldwide, strategic collaboration with Gilead Sciences, Inc., to develop Tarmogens for the treatment of chronic hepatitis B infection. For additional information, please visit the company's website at www.globeimmune.com.

###

GlobeImmune Contact:
Kirk Christoffersen
Senior Director Corporate Development
T: 303-625-2777
[email protected]

INVESTOR CONTACT:
Susan Noonan
S.A. Noonan Communications, LLC
T: 212-966-3650
[email protected]

Media Contacts:
Lena Evans or Tony Russo, Ph.D.
Russo Partners, LLC
T: 212-845-4262 or 212-845-4251
[email protected]
[email protected]

Copyright Thomson Reuters


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: %s via Thomson Reuters ONE


[HUG#1693969]